NOT MEDICAL ADVICE. No information on this site should be considered medical advice. Research peptides are not intended for human consumption — in-vitro lab use only. Consult a physician prior to introducing anything into the human body.
Peptide HubResearch Peptide Wiki
Support Us Join

Retatrutide, Explained: A Beginner’s Guide to the Triple Agonist

Retatrutide is an investigational peptide that activates three metabolic receptors at once, and it is the most hyped molecule in the research-peptide catalog. It is also still mid-trial. Here is what the hype is actually built on.

What it is

Retatrutide (development code LY3437943, from Eli Lilly) is a single synthetic peptide designed to activate the receptors for three hormones: GLP-1, GIP, and glucagon. Each target has its own history — GLP-1 drugs are approved for diabetes and obesity, GIP is the older incretin, and glucagon is best known for raising blood glucose and increasing energy expenditure. The triple-agonist bet is that activating all three together, in one molecule, produces more weight loss with a tolerable side-effect profile than any single target alone.

Where it stands in research

Phase 1 is complete, phase 2 is published (NEJM, 2023), and a broad phase 3 program — the TRIUMPH studies, spanning several populations — is underway, with full results not yet published at the time of writing. Retatrutide is not approved by any regulatory agency. Authorized use today means a clinical trial; anything sold as “retatrutide” in open channels is an unapproved research chemical of unverified provenance.

What the published phase 2 data showed: a randomized, placebo-controlled study of roughly 338 adults with overweight or obesity, dosed once weekly for up to 48 weeks. Weight loss was dose-dependent, and the highest-dose group was reported to average about 17.5% loss by week 24 and roughly 24% by week 48 — figures you will see quoted everywhere, usually without the qualifiers “single study, group average, phase 2.”

Dosing in a research context

In the trial, dosing was once weekly by subcutaneous injection, with gradual multi-step titration over the first months — starting low and escalating slowly — because abrupt high doses produced gastrointestinal intolerance in earlier testing. There is no established research dose for this molecule; any protocol found online is extrapolation from trial arms. Note the unit: retatrutide is dosed in milligrams, not micrograms, which already marks it as a different pharmacological animal from most peptides in research channels.

Practical cautions for researchers

  • Most reported side effects in trials were gastrointestinal — nausea, vomiting, diarrhea, constipation — concentrated early on and around dose increases; increases in resting heart rate have also been reported for this drug class.
  • The meaningful unknowns: long-term safety beyond one year, cardiovascular outcomes, muscle-versus-fat composition of the loss, and behavior after discontinuation. Phase 3 is designed to answer several of these; it has not answered them yet.
  • Gray-market vials labeled “retatrutide” have circulated for years with no approved product to benchmark against. Identity, purity, endotoxin, and actual fill are unverified, and lot-matched COAs plus independent retesting are the minimum diligence.
  • Everything above summarizes published trial reports in a research context; it is not guidance for human use of an unapproved compound.

The bottom line

A genuinely novel triple agonist with one of the strongest early weight-loss signals in a decade — and precisely because of that, one of the most counterfeited, mislabeled, and over-interpreted peptides in circulation. Read the primary literature, not the vendor blog. For the deeper look, see our pieces on reading the phase 2 data, on appetite claims, and on what is hype.